Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (91-100 of 367) with videos related to

Pageof 37
Sort By:
The Oncologist|November 4, 2020
Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team ApproachSanjay Popat, Neal Navani, Keith M Kerr, et al.
Respiratory Medicine Case Reports|June 2, 2015
Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reactionRomane M Schook, Lyan Koudstaal, Emile F Comans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2012
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomesErik C J Phernambucq, Koen J Hartemink, Egbert F Smit, et al.
Cancers|November 13, 2020
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical ResistanceRichard J Honeywell, Ietje Kathmann, Elisa Giovannetti, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort studyMichiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2018
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLCBianca van Veggel, Adrianus J de Langen, Sayed M S Hashemi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2010
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Egbert F Smit, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013Chris Dickhoff, Max Dahele, A Joop de Langen, et al.
Acta Ophthalmologica|February 17, 2015
Acquired ocular toxoplasmosis in a patient with thymomaChantal M van Luijk, Tom Missotten, Egbert F Smit, et al.
Journal of Clinical Pathology|February 10, 2015
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitorJustine L Kuiper, Merle I Ronden, Annemarie Becker, et al.
Pageof 37

Showing results (91-100 of 367) with videos related to

Sort By:
Pageof 37
The Oncologist|November 4, 2020
Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team ApproachSanjay Popat, Neal Navani, Keith M Kerr, et al.
Respiratory Medicine Case Reports|June 2, 2015
Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reactionRomane M Schook, Lyan Koudstaal, Emile F Comans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2012
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomesErik C J Phernambucq, Koen J Hartemink, Egbert F Smit, et al.
Cancers|November 13, 2020
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical ResistanceRichard J Honeywell, Ietje Kathmann, Elisa Giovannetti, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort studyMichiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2018
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLCBianca van Veggel, Adrianus J de Langen, Sayed M S Hashemi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2010
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Egbert F Smit, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013Chris Dickhoff, Max Dahele, A Joop de Langen, et al.
Acta Ophthalmologica|February 17, 2015
Acquired ocular toxoplasmosis in a patient with thymomaChantal M van Luijk, Tom Missotten, Egbert F Smit, et al.
Journal of Clinical Pathology|February 10, 2015
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitorJustine L Kuiper, Merle I Ronden, Annemarie Becker, et al.
Pageof 37